Results 201 to 210 of about 295,397 (306)

Urine Afamin as a biomarker of lupus nephritis. [PDF]

Front Immunol
Lin S, Du M, Wang J, Lai P, Yao G, Chen W, Xu X, Sun L.   +7 more
europepmc   +1 more source

Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large‐scale analysis of genetic predisposition and disease subtypes

Journal of Internal Medicine, Volume 299, Issue 1, Page 95-108, January 2026.
Abstract Background Systemic lupus erythematosus (SLE) is an autoimmune disease with a heterogenous clinical picture. This study aimed to link genetic SLE predisposition with relevant clinical manifestations. Method Datasets best corresponding to the 11 American College of Rheumatology 1982 (ACR‐82) classification criteria for SLE in a large, public ...
Sarah Reid, Johanna K. Sandling, Pascal Pucholt, Ahmed Sayadi, Martina Frodlund, Karoline Lerang, Iva Gunnarsson, Andreas Jönsen, Ann‐Christine Syvänen, Øyvind Molberg, Solbritt Rantapää‐Dahlqvist, Anna Rudin, Christopher Sjöwall, Elisabet Svenungsson, Anders A. Bengtsson, Lars Rönnblom, Dag Leonard   +16 more
wiley   +1 more source

A Pooled Analysis of Sex Differences in Lupus Nephritis. [PDF]

Kidney Int Rep
Nasr KK, Coopergard RB, Ma S, Chan TM, Rathi M, Houssiau FA, Hruskova Z, Jha V, Solomons N, Korbet SM, Romero-Diaz J, Sanchez-Guerrero J, Tesar V, Truman M, Mejia-Vilet J, West MR, Rovin BH, Nachman PH.   +17 more
europepmc   +1 more source

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

HLA, Volume 107, Issue 1, January 2026.
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk, Ilse Gille, Carolt Arana, Jordi Rovira, Eduard Palou, Fritz Diekmann, Dave L. Roelen, Mirjam H. M. Heemskerk, Sebastiaan Heidt   +8 more
wiley   +1 more source

Not So Benign: Revisiting Pure Membranous Lupus Nephritis. [PDF]

J Pers Med
Uzzo M, Calatroni M, Moroni GL.
europepmc   +1 more source

Interleukin-17 as a biomarker for lupus nephritis: correlation with disease activity indices and histopathological classification [PDF]

Aya Ahmed, Abdullatif A. Ahmed, Faten Ismail, Sahar A. Elsayed   +3 more
openalex   +1 more source

High Phosphate Load Induces De Novo Formation of Tertiary Lymphoid Structures in the Kidney

The FASEB Journal, Volume 39, Issue 24, 31 December 2025.
Graphical illustration of renal alterations under varying phosphate load: High phosphate load induces fibrosis, tubular injury, impaired renal function, and de novo formation of perivascular tertiary lymphoid structures. Under normal phosphate load, fibrosis, functional decline, and tubular injury are absent, while T‐ and B‐ cell aggregates are present
Nina Weingärtner, Beatrice Richter, Franziska Walles, Tamar Kapanadze, Jessica Schmitz, Jan H. Bräsen, Florian P. Limbourg, Dieter Haffner, Maren Leifheit‐Nestler   +8 more
wiley   +1 more source

Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre [PDF]

, 2001
D. Lê Thi Huong, B Wechsler, D Vauthier-Brouzes, H Beaufils, G Lefebvre, J-C Piette   +5 more
openalex   +1 more source

Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL. [PDF]

Ren Fail
Yang X, Liu S, Liu XJ, Wen D, Zhou Y, Zeng Y, Li L, Deng Q, Wang Y, Chen Q, Lv J.   +10 more
europepmc   +1 more source

ASSOCIATION BETWEEN LUPUS NEPHRITIS AND RENAL CANCER: A CASE REPORT

Teresinha Ponte, Thayane Furtado Rolim Lima, E. Rodrigues, Jean Carlos Alves de Lima Souza, Lysiane Maria Adeodato Ramos Fontenelle   +4 more
openalex   +1 more source